NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers

   NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable
              Profiling of Various Hematologic and Solid Cancers

PR Newswire

FT. MYERS, Fla., Jan. 30, 2014

FT. MYERS, Fla., Jan. 30, 2014 /PRNewswire/ --NeoGenomics, Inc. (NASDAQ:
NEO), a leading provider of cancer-focused genetic and molecular testing
services, announced today that it has validated and launched a series of
NeoTYPE cancer profiling tests covering 22 different categories of cancer.
Each of these tests is designed to investigate the most common and actionable
genomic abnormalities reported for that particular tumor.

The 22 categories of tumors covered in this series of tests are: brain, lung,
breast, cervix, colorectal, endometrium, esophagus, stomach, ovary, soft
tissue, thyroid, GIST (gastro intestinal stromal tumors), melanoma, acute
myeloid leukemia (AML), myelodysplastic syndrome (MDS), AML favorable-risk,
chronic lymphocytic leukemia (CLL), lymphoma, juvenile myelomonocytic leukemia
(JMML), myeloproliferative neoplasms (MPN), cancer not-otherwise specified,
and spliceosomal abnormalities. The genetic abnormalities are investigated
using the most reliable technology including sequencing, Fluorescent In-Situ
Hybridization (FISH), methylation analysis, fragment length analysis and
SNP-cytogenetic array technology.

Although more than 60 different genes are investigated in all these tumors,
only 8 - 18 genes are investigated per patient or tumor type. For each type
of cancer, we selected the key driver genes that are central to confirming
diagnosis, predicting prognosis, determining or monitoring therapy, and
exploring clinical trials options. In many cases, these driver genes can
also be targeted for therapy. 

Doug VanOort, the company's Chairman and CEO, said "Precision medicine
requires precision testing. Our targeted tests are responsive to the need for
both comprehensive testing in complex cases and the need to be cost sensitive
for patients and insurance companies.  Therefore, we are launching these
tests on both a "comprehensive" and a "concise" basis. We believe this
flexibility will meet the needs of the scientific community and our clients."


Dr. Maher Albitar, the Company's Chief Medical Officer and Director of
Research and Development, commented, "Classifying cancers based on their
morphology and site of origin is no longer adequate for the practice of
evidence-based medicine. Our molecular profiling testing is a reliable and
concise approach to sub-classifying these tumors based on their underlying
driving biology. This enables clinicians to better manage and treat their
patients. Our testing is designed to find actionable molecular abnormalities
without testing hundreds of genes."

About NeoGenomics, Inc.

NeoGenomics, Inc. is a high-complexity CLIA–certified clinical laboratory that
specializes in cancer genetics testing, the fastest growing segment of the
laboratory industry. The company's testing services include cytogenetics,
fluorescence in-situ hybridization (FISH), flow cytometry,
immunohistochemistry, morphology studies, anatomic pathology and molecular
genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in
Nashville, TN, Irvine, CA, Tampa, FL and Fort Myers, FL. NeoGenomics services
the needs of pathologists, oncologists, urologists and other clinicians, and
hospitals throughout the United States. For additional information about
NeoGenomics, visit http://www.neogenomics.com.

Forward Looking Statements

Except for historical information, all of the statements, expectations and
assumptions contained in the foregoing are forward-looking statements. These
forward looking statements involve a number of risks and uncertainties that
could cause actual future results to differ materially from those anticipated
in the forward looking statements. Actual results could differ materially
from such statements expressed or implied herein. Factors that might cause
such a difference include, among others, the company's ability to continue
gaining new customers, offer new types of tests, and otherwise implement its
business plan. As a result, this press release should be read in conjunction
with the company's periodic filings with the SEC.

SOURCE NeoGenomics, Inc.

Website: http://www.neogenomics.org
Contact: NeoGenomics, Inc., Steven C. Jones, Director of Investor Relations,
(239) 325-2001, sjones@neogenomics.com, or Hawk Associates, Inc., Ms. Julie
Marshall, (305) 451-1888, neogenomics@hawkassociates.com
 
Press spacebar to pause and continue. Press esc to stop.